EAACI Congress 2025
BackTPS71 - Mastocytosis and mast cells
Sunday 15 Jun, 12:45 PM -
13:45 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
"Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"
Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes
Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity
Hereditary Alpha-Tryptasemia: A Case Series
MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin
Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases
The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis
